HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a ...

DENVER — Adding the weight-loss drug tirzepatide to the biologic ixekizumab significantly improved joint and skin outcomes in ...

Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...

April 2 () - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...

Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need for ...

The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and CKD had a greater UACR reduction with finerenone plus empagliflozin vs. either ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

Researchers plan to begin the first patient trial in 2027 thanks to promising preclinical results from a gene therapy ...

A combination of brexpiprazole (Rexulti) and sertraline improved post-traumatic stress disorder (PTSD) symptoms more than sertraline alone, a phase III trial found. The primary endpoint was the change ...

Most patients with PAH (77.7%) were initiated on monotherapy, with a median delay of 43 days before receiving medication.

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.